EP1469822A2 - Kosmetische oder dermatologische zubereitungen, enthaltend bor-organische verbindungen, zur vermei dung von hautschädigungen durch peroxide - Google Patents

Kosmetische oder dermatologische zubereitungen, enthaltend bor-organische verbindungen, zur vermei dung von hautschädigungen durch peroxide

Info

Publication number
EP1469822A2
EP1469822A2 EP03704347A EP03704347A EP1469822A2 EP 1469822 A2 EP1469822 A2 EP 1469822A2 EP 03704347 A EP03704347 A EP 03704347A EP 03704347 A EP03704347 A EP 03704347A EP 1469822 A2 EP1469822 A2 EP 1469822A2
Authority
EP
European Patent Office
Prior art keywords
boron
containing compound
formula
cosmetic
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03704347A
Other languages
German (de)
English (en)
French (fr)
Inventor
Axel Jentzsch
Sylke Haremza
Gerhard Wagenblast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2002102065 external-priority patent/DE10202065A1/de
Application filed by BASF SE filed Critical BASF SE
Publication of EP1469822A2 publication Critical patent/EP1469822A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
    • A61Q1/06—Lipsticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners

Definitions

  • the invention relates to the use of peroxide decomposers and a combination of antioxidants and peroxide decomposers which react faster with the peroxides than the skin's own sulfur-containing compounds with peroxides or hydroperoxides by reduction without the formation of radical subsequent steps, and to cosmetic and dermatological preparations, that contain these peroxide decomposers.
  • Human skin is subject to certain aging processes, which are partly due to intrinsic processes (chronoaging) and partly to exogenous factors (environmental, e.g. photoaging).
  • aging processes which are partly due to intrinsic processes (chronoaging) and partly to exogenous factors (environmental, e.g. photoaging).
  • environmental, e.g. photoaging there are temporary or permanent changes in the skin, such as acne, oily or dry skin, keratoses, rosaceae, photosensitive, inflammatory, erythematous, allergic or autoimmune-reactive reactions such as dermatoses, photodermatoses and others, their exact causes and factors that influence them. are often only incompletely understood.
  • the exogenous factors include, in particular, sunlight or artificial radiation sources with a comparable spectrum, as well as compounds that can arise from the radiation, such as undefined reactive photo products, which can also be radical or ionic.
  • these factors also include harmful or reactive compounds such as ozone, free radicals, for example the hydroxyl radical, singlet oxygen and other reactive oxygen or nitrogen compounds, cigarette smoke, natural and synthetic toxins, and others which disrupt the natural physiology or morphology of the skin.
  • harmful or reactive compounds such as ozone, free radicals, for example the hydroxyl radical, singlet oxygen and other reactive oxygen or nitrogen compounds, cigarette smoke, natural and synthetic toxins, and others which disrupt the natural physiology or morphology of the skin.
  • the influence of these factors leads, among other things, to direct damage to the DNA of the skin cells and the collagen, elastin or glycosaminoglycan molecules of the extracellular matrix, which are responsible for the firmness of the skin.
  • signal transduction chains are influenced, at the end of which is the activation of harmful factors, for example matrix-degrading enzymes.
  • harmful factors for example matrix-degrading enzymes.
  • MMPs matrix metalloproteinases
  • TIMPs tissue inhibitor of matrix metalloproteinases
  • inflammatory reactions can occur, among other things, unregulatory compounds such as interleukins, prostaglandins and histamines are released. Among other things, this attracts immune-competent cells and increases the inflammatory response.
  • the consequences of aging are thinning of the skin, weaker interlocking of the epidermis and Dennis, reduction in the number of cells and the supplying blood vessels.
  • the aging processes lead to the formation of fine lines and wrinkles, the skin becomes leathery, yellowish and sagging, and pigment disorders occur.
  • Antioxidative compounds are often used in dermatological or cosmetic preparations to protect against spoilage. In addition, they can also be used to reduce harmful or undesirable oxidative processes that take place in human or animal skin. Such processes are known to play an important role in skin aging.
  • the skin is permanently exposed to oxidative stress through the formation of peroxides and hydroperoxides, some of which come from the external environment of the skin, but some are also endogenous.
  • the skin has a number of its own protective mechanisms. However, these protective mechanisms are not sufficient to completely prevent oxidative processes in the skin. On the contrary, it is generally assumed that these oxidative processes make a significant contribution to skin aging, but also to general or pathological changes in the skin.
  • cysteine-containing dipeptides for skin bleaching, for preventing lipid peroxidation and for the decomposition of lipid peroxides is known from JP 06345797.
  • active ingredients are therefore added to cosmetic and dermatological preparations in an antioxidative manner, ie as a 0 or C radical scavenger (for example DE 19739349).
  • a 0 or C radical scavenger for example DE 19739349.
  • the effect actually achieved has so far lagged behind the hoped-for effect.
  • a correspondingly higher antioxidative effect cannot generally be achieved by increasing the amount of antioxidant added.
  • the object was therefore to provide active ingredients for cosmetic or dermatological preparations with which the antioxidative effect can be increased considerably.
  • cosmetic or dermatological preparations which have an effective content of 10 a) at least one antioxidant and effective as an O- or C-radical scavenger
  • the preparations according to the invention are particularly suitable for avoiding or reducing skin damage caused by endogenously or exogenously formed peroxides or hydroperoxides.
  • the cosmetic or dermatological preparations generally contain, based on the finished preparations, 0.001 to 25% by weight, preferably 0.01 to 10% by weight and in particular 1 to 5% by weight of antioxidant (a) and 0.001 up to 30% by weight, preferably 0.01 to 10% by weight and in particular 1 to 5% by weight of at least one peroxide or hydroperoxide decomposer (b).
  • peroxide and hydroperoxide decomposers (b) have a significantly greater decomposing (reducing) effect than the skin's own compounds such as cystine or cysteine. Whether certain compounds are suitable for the use according to the invention can be seen in vitro e.g. remembering that they solved at room temperature
  • the peroxide or hydroperoxide concentration by at least 10%, in particular 20%, preferably 50% and in particular 90% decrease.
  • 40 concentration is usually 0.5 m / L.
  • Another object of the present invention relates to the use of organic, boron-containing compounds b), which reduces peroxides or hydroperoxides to the corresponding alcohols 45 without the formation of active radical subsequent steps, in cosmetic or dermatological preparations.
  • Another subject relates to the use of a combination of
  • At least one antioxidant effective as a 0 or C radical scavenger
  • suitable boron-containing compounds b) are compounds of the formula (I)
  • Suitable as b) are compounds of the formula (III)
  • Suitable as b) are compounds of the formula (IV):
  • R 1 and R 2 have the meaning given above and R 1 and R 2 can be bridged by ring closure.
  • Suitable as b) are compounds of the formula (V):
  • R 4 can have the following meaning
  • Suitable as b) are compounds of the formula (VI)
  • R 1 , R 2 and R 3 have the meanings given above.
  • Suitable as b) are compounds of the formula (VII)
  • R 1 , R 2 and R 3 have the meanings given above.
  • Suitable as b) are compounds of the formula (VIII)
  • X ⁇ physiologically compatible cations such as the alkali and alkaline earth metal salts or as optionally substituted ammonium salts.
  • Suitable as b) are compounds of the formula (IX):
  • R 1 to R 4 are branched or unbranched C 1 -C 2 -alkyl chains, preferably methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1, 1 -Dimethyl-ethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1, 1-dimethylpropyl, 1,2-dirnethylpropyl, 1-methylpentyl , 2-Methylpentyl, 3-Methylpentyl, 4-Methylpentyl, 1, 1-Dimethylbutyl, 1, 2-Dimethylbutyl, 1, 3-Dirnethylbutyl, 2,2-Dirnethylbutyl, 2,3-Dirnethylbuty
  • alkyl radicals are methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1, 1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methyl - Butyl, 3-methylbutyl, 2, 2-Dirnethylpropyl, 2-ethylhexyl called.
  • the alkyl radicals can optionally be substituted with one or more radicals such as halogen (e.g. fluorine, chlorine or bromine), cyano, nitro, amino, hydroxy or heteroatoms such as sulfur, nitrogen or silicon, the free valences of which can be saturated by hydrogen.
  • halogen e.g. fluorine, chlorine or bromine
  • cyano nitro, amino, hydroxy or heteroatoms
  • sulfur, nitrogen or silicon the free valences of which can be saturated by hydrogen.
  • alkenyl radicals R 1 to R 4 are branched or unbranched CC 10 alkenyl chains, preferably vinyl, propenyl, isopropenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 2-methyl-1-butenyl, 2-methyl -2-butenyl, 3-methyl-1-butenyl, 1-hexenyl, 2-hexenyl, 1-heptenyl, 2-heptenyl, 1-octenyl or 2-octenyl.
  • the radicals R 1 to R 4 can be bridged by ring closure.
  • Preferred cycloalkyl radicals for R 1 to R 4 are branched or unbranched C 3 -C 10 -cycloalkyl chains such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-methylcyclopropyl, 1-ethylcyclopropyl, 1-propylcyclopropyl, 1-butylcyclopropyl, 1-pentylcyclopropyl, 1-methyl-l-butylcyclopropyl, 1,2-dimethyl-cyclypropyl, l-methyl-2-ethylcyclopropyl, cyclooctyl, cyclononyl or cyclodecyl.
  • the preferred cycloalkenyl radicals for R 1 to R 4 are branched or unbranched, C 3 -CiQ-cycloalkenyl chains with one or more double bonds such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, 1, 3-cyclohexadienyl, 1,4-cyclohexadienyl, cycloheptenyl, cycloheptatrienyl, cyclo-octenyl, 1,5-cyclooctadienyl, cyclooctatetraenyl, cyclononenyl or cyclodecyl.
  • Cyclopropyl, cyclopentyl and cyclohexyl are particularly preferred.
  • the cycloalkenyl and cycloalkyl radicals can if necessary. with one or more, e.g. B. 1 to 3 radicals such as halogen (e.g. fluorine, chlorine or bromine), Cya.no, nitro, amino, C 1 -C 4 -alkylamino, C ⁇ -C 4 -dialkylamino, hydroxy, C ⁇ -C 4 alkyl, C ⁇ -C4-alkoxy or other radicals be substituted or 1 to 3 heteroatoms such as sulfur, nitrogen,
  • halogen e.g. fluorine, chlorine or bromine
  • Cya.no, nitro, amino, C 1 -C 4 -alkylamino, C ⁇ -C 4 -dialkylamino, hydroxy, C ⁇ -C 4 alkyl, C ⁇ -C4-alkoxy or other radicals be substituted or 1 to 3 hetero
  • Silicon whose free valences can be saturated by hydrogen or -CC 4 alkyl or contain oxygen in the ring.
  • Suitable alkoxy radicals are those having 1 to 12 carbon atoms, preferably 15 having 1 to 8 carbon atoms.
  • Examples include:
  • Alkoxycarbonyl radicals are, for example. Esters, the above-mentioned alkoxy radicals or residues of higher alcohols e.g. containing up to 30 20 carbon atoms, such as iso-cis alcohol.
  • Suitable mono- or dialkylamino radicals are those which contain alkyl radicals having 1 to 12 carbon atoms, such as, for. B. methyl, n-propyl, n-butyl, 2-methylpropyl, 1, 1-dimethylpropyl, 35 hexyl, heptyl, 2-ethylhexyl, isopropyl, 1-methylpropyl, n- Pentyl-, 3-methylbutyl-, 2,2-dryness ethylpropyl-, 1-methyl-l-ethylpropyl- and octyl.
  • Aryl is understood to mean aromatic rings or ring systems with 6 to 40 18 carbon atoms in the ring system, for example phenyl or naphthyl, which may be with one or more residues such as halogen z.
  • Heteroaryl radicals are advantageously simple or fused aromatic ring systems with one or more heteroaromatic 3- to 7-membered rings.
  • One or more nitrogen, sulfur and / or oxygen atoms can be contained in the ring or ring system as heteroatoms.
  • the cations of the alkali and alkaline earth metal salts or the optionally substituted ammonium salts are suitable as physiologically compatible cations.
  • examples include the trialkylammonium salts, such as tri (hydroxyalkyl) ammonium salts or the 2-methylpropan-l-ol-2-ammonium salts.
  • Ammonium residues, in particular alkylammonium residues, are also suitable.
  • the selection from the abovementioned compounds is made on the basis of the skin compatibility or the skin compatible concentration and the effectiveness of the peroxide or hydroperoxide decomposition.
  • the compound in question is dissolved in a polar solvent (e.g. acetic acid) or a non-polar solvent (e.g. toluene) in a molar concentration of 0.055 m / L and the reaction conversion is measured by one Peroxide or hydroperoxide after storage at 70 ° C for 30 minutes.
  • the concentration of the peroxide or hydroperoxide should be reduced by at least 10%, in particular 20%, preferably 50% and in particular 90%.
  • the peroxide or hydroperoxide concentration is usually 0.5 m / L.
  • the antioxidants (a) are generally known compounds.
  • the antioxidants are advantageously selected from the groups of carotenoids, carotenes (eg .alpha.-carotene, .beta.-carotene, lycopene) and their derivatives, chloro-ogensic acid and their derivatives, lipoic acid and their derivatives (e.g. dihydroliponic acid) (Metal) chelators, EDTA, EGTA and their derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g. vitamin E acetate), vitamin A and
  • vitamin A palmitate vitamin A palmitate
  • butylated hydroxytoluene butylated hydroxy anisole
  • other antioxidants commonly used in cosmetic preparations.
  • the amount of the aforementioned antioxidants (a) in the finished preparations is, for example. 0.001 to 30% by weight, preferably 0.01 to 10% by weight and in particular 1 to 5% by weight.
  • the cosmetic and dermatological preparations according to the invention offer effective protection
  • the new cosmetic and dermatological formulations can be composed as usual with regard to their other constituents and can be used for the treatment, care and cleaning of the skin in cosmetics.
  • the composition depends on the effectiveness of the inhibitor, the penetration properties of the active substance through the stratum corneum and its ability to form a depot in the skin.
  • prematurely aged skin e.g. wrinkles, age spots, telangiectasias, pigment disorders
  • prematurely aged skin appendages e.g. wrinkles, age spots, telangiectasias, pigment disorders
  • Skin and / or the appendages of the skin in particular acne, oily or dry skin, keratoses, rosaceae, dermatoses, atopic eczema, seborrheic eczema, photodermatoses, polymorphic light dermatosis
  • skin in particular acne, oily or dry skin, keratoses, rosaceae, dermatoses, atopic eczema, seborrheic eczema, photodermatoses, polymorphic light dermatosis
  • the cosmetic and dermatological preparations according to the invention are applied to the skin (and / or the hair) in a sufficient amount in the manner customary for cosmetics.
  • the active ingredients according to the invention are used in cosmetic compositions for cleaning the skin, such as bar soaps, toilet soaps, core soaps, transparent soaps, luxury soaps, deodorant soaps, cream soaps, baby soaps, skin protection soaps, abrasive soaps, syndets, liquid soaps, pasty soaps, lubricating soaps, washing pastes, liquid washing, showering and bathing preparations, for example Wash lotions, shower baths, shower gels, foam baths, cream foam baths, oil baths, bath extracts, scrub preparations, in-situ products, shaving foams, shaving lotions, shaving creams.
  • cosmetic compositions for cleaning the skin such as bar soaps, toilet soaps, core soaps, transparent soaps, luxury soaps, deodorant soaps, cream soaps, baby soaps, skin protection soaps, abrasive soaps, syndets, liquid soaps, pasty soaps, lubricating soaps, washing pastes, liquid washing, showering and bathing preparations, for example Wash
  • the active compounds according to the invention can be used in cosmetic agents for hair care, such as hair treatments, hair lotions, hair rinses, hair emulsions, tip fluids, leveling agents for perms, hot oil treatment preparations, conditioners, setting lotions, shampoos, hair tinting and coloring agents, hair sprays, hair dryer lotions, setting lotions, Shine sprays, hair brilliants, hair styling products, hair lotions, alopecia care products and others can be used.
  • cosmetic agents for hair care such as hair treatments, hair lotions, hair rinses, hair emulsions, tip fluids, leveling agents for perms, hot oil treatment preparations, conditioners, setting lotions, shampoos, hair tinting and coloring agents, hair sprays, hair dryer lotions, setting lotions, Shine sprays, hair brilliants, hair styling products, hair lotions, alopecia care products and others can be used.
  • the cosmetic or dermatological preparations can be prepared as a spray (pump spray or aerosol), foam, gel, gel spray, lotion, cream, mousse, ointment, suspensions or powder. It is also advantageous to present the active ingredients in encapsulated form, for example as cellulose encapsulation, in gelatin, with polyamides, in niosomes, wax matrices, with cyclodextrins or with liposomal encapsulation.
  • the preparations according to the invention generally contain other auxiliaries, as are usually used in such preparations, e.g. Preservatives, bactericides, perfumes, substances to prevent foaming, dyes, pigments, thickeners, surface-active substances, emulsifiers, softening substances, softeners, fats, oils, waxes or other usual components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers , Solubilizers, electrolytes, organic acids, organic solvents or silicone derivatives.
  • auxiliaries e.g. Preservatives, bactericides, perfumes, substances to prevent foaming, dyes, pigments, thickeners, surface-active substances, emulsifiers, softening substances, softeners, fats, oils, waxes or other usual components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers , Solubilizers, electrolytes, organic acids, organic solvents or silicone derivative
  • the preparations according to the invention can contain further compounds which have an antioxidative effect, as a radical scavenger, moisturize or moisturize the skin, have an anti-rythematous, anti-inflammatory or anti-allergic effect in order to supplement or intensify their action.
  • these compounds can be selected from the group of vitamins, plant extracts, alpha and beta hydroxy acids, ceramides, anti-inflammatory, anti-microbial or UV-filtering substances, as well as their derivatives and mixtures thereof.
  • Preparations according to the invention can also advantageously contain substances which absorb UV radiation in the UV-B and / or UV-A range.
  • the lipid phase is advantageously selected from the group of substances of mineral oils, mineral waxes, branched and / or unbranched hydrocarbons and waxes, triglycerides of saturated and / or unsaturated, branched and / or unbranched C 8 -C 24 alkane carboxylic acids; they can be selected from synthetic, semi-synthetic or natural oils such as olive oil, palm oil, almond oil or mixtures; Oils, fats or waxes, esters of saturated and / or unsaturated, branched and / or unbranched C 3 -C 3 o-alkane carboxylic acids and saturated and / or unsaturated, branched and / or unbranched C 3 -C 30 alcohols aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched C 3 -C 30 alcohols, for example isopropyl myristate, isopropyl stearate, hexyldecyl stea
  • the aqueous phase of the preparations according to the invention optionally advantageously contains alcohols, diols or polyols with a low C number, and also their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol monoethyl ether.
  • emulsifiers such as polyglycerol esters, sorbitan esters or partially esterified glycerides are preferred as emulsifiers.
  • Suitable solubilizers include, in particular, ethoxylated sorbitan esters, ethoxylated lanolin alcohols and ethoxylated castor oil.
  • Typical native and synthetic thickeners or gel formers in formulations are crosslinked polyacrylic acids and their derivatives, polysaccharides such as xanthan gu or alginates, carboxymethyl cellulose or hydroxycarboxymethyl cellulose, hydrocolloids such as gum arabic or momorillonite minerals such as bentonites or fatty alcohols, polyvinyl alcohol and polyvinyl pyrrolidone.
  • Suitable propellants for aerosols according to the invention are the customary propellants, for example propane, butane, pentane and others.
  • a suitable solvent can be Toulene-d8 or CD 3 COOD.
  • the measurement solutions were prepared from this by mixing 350 ⁇ l of solution 1 and 350 ⁇ l of the respective solution 2; the measurement solution was immediately placed in an NMR tube and transferred to the NMR device. The solutions were always prepared and the measurements were carried out at 22 ° C. Before the measurement, the solutions were stored in a thermostat at 70 ° C for 30 minutes. All measurements were carried out on the INOVA 500 500 MHz NMR spectrometer from Varian. An iH-NMR spectrum and a 2D-HSQC ( ⁇ H / 13 C) spectrum were recorded from each measurement solution. Tert. -Butyl hydroperoxide and tert.
  • Cetearyl octanoate 2.50 aluminum stearate 0.25
  • Panthenol 0.50 Water and Tocopheryl Acetate and Polysorbate 80 and Caprylic / Capric Triglyceride and Lecithin 3.00
  • Lactic Acid (80%) 0.20 peroxide decomposer according to Examples 1 to 6 2.50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03704347A 2002-01-18 2003-01-03 Kosmetische oder dermatologische zubereitungen, enthaltend bor-organische verbindungen, zur vermei dung von hautschädigungen durch peroxide Withdrawn EP1469822A2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10202065 2002-01-18
DE2002102065 DE10202065A1 (de) 2002-01-18 2002-01-18 Kosmetische oder dermatologische Zubereitungen zur Vermeidung von Hautschädigungen durch Peroxide
DE10203414 2002-01-28
DE10203414 2002-01-28
PCT/EP2003/000014 WO2003059312A2 (de) 2002-01-18 2003-01-03 Kosmetische oder dermatologische zubereitungen, enthaltend bor-organische verbindungen zur vermeidung von hautschädigungen durch peroxide

Publications (1)

Publication Number Publication Date
EP1469822A2 true EP1469822A2 (de) 2004-10-27

Family

ID=26010947

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03704347A Withdrawn EP1469822A2 (de) 2002-01-18 2003-01-03 Kosmetische oder dermatologische zubereitungen, enthaltend bor-organische verbindungen, zur vermei dung von hautschädigungen durch peroxide

Country Status (8)

Country Link
US (1) US20050118209A1 (ja)
EP (1) EP1469822A2 (ja)
JP (1) JP2006502962A (ja)
CN (1) CN1617706A (ja)
AU (1) AU2003206690A1 (ja)
CA (1) CA2471712A1 (ja)
MX (1) MXPA04006489A (ja)
WO (1) WO2003059312A2 (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2410587T3 (es) 2004-01-22 2013-07-02 University Of Miami Formulaciones tópicas de coenzima Q10 y métodos de uso
PL1893622T3 (pl) * 2005-06-13 2010-02-26 Basf Se Sposób wytwarzania dialkoksyorganoboranów
WO2007060117A2 (de) * 2005-11-24 2007-05-31 Basf Se Chimäre keratinbindende effektorproteine
US8288512B2 (en) 2006-01-20 2012-10-16 Basf Se Use of amphiphilic self-assembling proteins for formulating poorly water-soluble effect substances
EP2136787B1 (en) 2007-03-22 2019-08-21 Berg LLC Topical formulations having enhanced bioavailability
WO2009081970A1 (ja) * 2007-12-26 2009-07-02 Eisai R & D Management Co., Ltd. ヘテロ環置換ピリジン誘導体の製造方法
JP2009184988A (ja) * 2008-02-07 2009-08-20 Institute Of Physical & Chemical Research 新規ホウ素化合物及びそれを含む細胞内カルシウム濃度調節剤又は医薬組成物
CN103462896A (zh) 2008-04-11 2013-12-25 细胞研究有限公司 诱导癌细胞凋亡的方法和应用
CN102176904B (zh) 2008-08-08 2014-06-25 巴斯夫欧洲公司 基于生物聚合物的包含活性物质的连续纤维层、其用途和产生方法
JP2011530661A (ja) * 2008-08-08 2011-12-22 ビーエーエスエフ ソシエタス・ヨーロピア 活性成分の制御放出を伴う有効成分含有繊維表面構造体、その使用、およびその生産のための方法
WO2010132479A2 (en) 2009-05-11 2010-11-18 Cytotech Labs, Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
SG10202010355PA (en) 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
US20130079305A1 (en) * 2010-05-31 2013-03-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. 3-substituted vinylboronates and uses thereof
FR2966153B1 (fr) * 2010-10-19 2013-05-17 Commissariat Energie Atomique Utilisation d'azaboronates cycliques comme materiaux sensibles dans des capteurs destines a detecter la presence de peroxydes dans un milieu gazeux
FR2973226B1 (fr) 2011-04-01 2013-03-29 Oreal Utilisation de composes (ethoxy-hydroxyphenyl)alkylcetone ou ethoxyhydroxyalkylphenol pour traiter la peau grasse
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
WO2012137164A1 (en) * 2011-04-07 2012-10-11 Biolinerx Ltd. Antimicrobial compositions, antibiofilm compositions and uses thereof
EA201490047A1 (ru) 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
KR102279451B1 (ko) 2013-04-08 2021-07-19 버그 엘엘씨 코엔자임 q10 병용 요법을 이용한 암 치료
JP6463349B2 (ja) * 2013-06-21 2019-01-30 ローム アンド ハース カンパニーＲｏｈｍ Ａｎｄ Ｈａａｓ Ｃｏｍｐａｎｙ ポリアクリレートオイルゲル及び方法
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
CN113683633B (zh) * 2021-08-31 2023-12-12 温州大学新材料与产业技术研究院 一种烷基硼酸酯的制备方法
CN113563372B (zh) * 2021-08-31 2023-12-12 温州大学新材料与产业技术研究院 一种烯基硼酸酯的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171875A (en) * 1991-01-11 1992-12-15 Lce Partnership Beta branched borate esters
WO1993016195A1 (en) * 1992-02-10 1993-08-19 British Technology Group Ltd. Chemiluminescent enhancers
JP3652835B2 (ja) * 1997-04-30 2005-05-25 豊 三嶋 色白剤
DE19950020A1 (de) * 1999-10-16 2001-04-19 Henkel Kgaa Verwendung von Zusammensetzungen zur pflegenden Behandlung der Haut

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03059312A2 *

Also Published As

Publication number Publication date
AU2003206690A1 (en) 2003-07-30
JP2006502962A (ja) 2006-01-26
CA2471712A1 (en) 2003-07-24
WO2003059312A3 (de) 2003-12-31
MXPA04006489A (es) 2004-10-04
WO2003059312A2 (de) 2003-07-24
US20050118209A1 (en) 2005-06-02
CN1617706A (zh) 2005-05-18

Similar Documents

Publication Publication Date Title
WO2003059312A2 (de) Kosmetische oder dermatologische zubereitungen, enthaltend bor-organische verbindungen zur vermeidung von hautschädigungen durch peroxide
DE60023792T2 (de) Karmin und Karamel enthaltende selbstbräunende Zusammensetzung
EP1307179A2 (de) Kosmetische oder dermatologische zubereitungen zur vermeidung von hautschädigungen durch peroxide
DE4228455A1 (de) Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Thiolen und/oder Thiolderivaten
EP0716847A1 (de) Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
DE10064818A1 (de) Verwendung von Chroman-Derivaten in kosmetischen oder dermatologischen Zubreitungen
EP0726273A1 (de) Tocopherylglycoside, ihre Herstellung sowie ihre Verwendung als Tenside, als Antioxidantien sowie als der Zellalterung vorbeugender Wirkstoff in kosmetischen oder pharmazeutischen Zubereitungen
DE10132338A1 (de) Verwendung von 5'-Desoxy-5'-methylthioadenosin in hautkosmetischen Mitteln
DE10128910A1 (de) Verwendung von Wirkstoffkombinationen aus Arginin und Ascorbinsäure zur Hautstraffung
EP0586961A1 (de) Kosmetische und dermatologische Formulierungen mit einem wirksamen Gehalt an cis-Urocaninsäure
DE19720339A1 (de) Wirkstoffe und Zubereitungen für die Hautaufhellung und zur Verhinderung der Hautbräunung
DE10032165A1 (de) Verwendung von physiologisch verträglichen Sulfinsäuren als Antioxidans oder Radikalfänger in kosmetischen oder dermatologischen Zubereitungen
DE69711779T2 (de) Neue Melatonin-Derivaten als Wirkstoff gegen freien Radikale sowie diese enthaltende Präparate
WO2006122721A2 (de) Verwendung von peroxidzersetzern in kosmetischen und pharmazeutischen mitteln zur behandlung der haut
WO2006122668A1 (de) Wirkstoffkombinationen aus glucosylglyceriden und kreatin und/oder kreatinin
EP2090290B1 (de) Verwendung von 3-(4-Hydroxy-3-methoxphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite
WO2002098386A2 (de) Verwendung von natriumpolystyrolsulfonat zur hautstraffung
DE10202065A1 (de) Kosmetische oder dermatologische Zubereitungen zur Vermeidung von Hautschädigungen durch Peroxide
DE60118196T2 (de) Verwendung von einem liponsäuren-(r)-enantiomeren in kosmetika und dermatologie
WO2007041884A1 (de) Topisch anwendbare zusammensetzung für die verwendung als hautaufhellungsmittel
DE4405585A1 (de) Verwendung von trans-Urocaninsäure als Antioxidans sowie zur Prophylaxe und Behandlung der Hautalterung
DE102008009799B4 (de) Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on gegen Hyperpigmentierung
DE10121069A1 (de) Verwendung von Tetrahydrocurcuminoiden oder deren Derivaten als Wirkstoffe zur Herstellung von kosmetischen und dermatologischen Zubereitungen zum Schutz und zur Behandlung der trockenen bzw. alterstrockenen Haut
DE10010814A1 (de) Verwendung von 4-Oxoretinol und dessen Derivaten in kosmetischen Zubereitungen
WO2002078686A1 (de) Retinylcarbonate in kosmetika und dermatika

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040818

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

RIC1 Information provided on ipc code assigned before grant

Ipc: C07F 5/02 20060101ALI20060908BHEP

Ipc: A61Q 5/00 20060101ALI20060908BHEP

Ipc: A61Q 17/04 20060101ALI20060908BHEP

Ipc: A61Q 19/08 20060101ALI20060908BHEP

Ipc: A61K 8/58 20060101AFI20060908BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070801